A Message from the President
Every June, we honor Cancer Immunotherapy Month, an opportunity to highlight advancements, acknowledge future potential and celebrate the individuals driving innovation in cancer immunotherapy. While we celebrate the paradigm shift in cancer care our community pioneered, we still have much to do. The SITC leadership is committed to driving the science of biomarker discovery, optimizing patient selection in early phase clinical trials so that the right patient finds the right immunotherapy at the right time.
Most recently, SITC published a commentary in the
Journal for ImmunoTherapy of Cancer (
JITC), “
A SITC Perspective: Leveraging Patient Enrichment Biomarkers to Accelerate Early Phase IO Drug Development.” The commentary outlines SITC’s strategy to use biomarker-based patient selection in early trials and refine predictive tools through advanced technologies like digital pathology, multi-omics, and AI. This approach aims to reduce the risk of late-stage trial failure and accelerate the delivery of effective IO therapies to patients.
Parallel to this commentary, SITC hosted a Leveraging Biomarkers Think Tank, co-organized by Carlo Bifulco, MD – Providence Genomics and Tullia Bruno, PhD – University of Pittsburgh. Here, a diverse group of leaders contributed to a discussion on strategies to leverage biomarkers in the enrichment of early-phase trials with patients best suited for response. Through concerted discussion, the experts worked to develop a framework for a biomarker-based enrichment strategy that incorporates the collaboration of spatial transcriptomics and proteomics, improved understanding of the tumor microenvironment, novel informative biomarkers, adaptive trial designs and standardized pathology.
Implementing a biomarker-based enrichment strategy will not only increase the likelihood of detecting meaningful clinical signals and accelerate IO drug development but may also lead to uncovering useful predictive biomarkers to guide clinical decision-making in the future.
James L. Gulley, MD, PhD, FACP
SITC President
Program Spotlight
|
Time is Running Out: Submit Your Abstract for SITC 2025!
|
|
Regular and Young Investigator Award (YIA) abstract submissions for SITC 2025 are open now through June 26 at 5 p.m. PT. In honor of SITC’s 40th Anniversary, 40 Young Investigator Travel Awards will be granted! All accepted abstracts will be published in a supplement in the Journal for ImmunoTherapy of Cancer (JITC) - the society’s global, open access, peer-reviewed journal.
We look forward to celebrating our milestone year with you at the Gaylord National Resort & Convention Center, Nov. 5–9, 2025!
|
|
SITC Summit on the Future of Neoadjuvant Clinical Trial Design
|
|
This virtual summit will explore two key topics: assessing the contribution of each treatment phase to overall clinical efficacy and defining endpoints in clinical trials of neoadjuvant or perioperative immunotherapies for early-stage resectable cancers.
Join SITC on Thursday, June 26, from 11 a.m.–3 p.m. EDT (5 p.m.–9 p.m. CEST - Central European Summer Time)!
|
|
SITC's Gastrointestinal Cancer Clinical Practice Guideline Update
|
|
SITC’s Gastrointestinal Cancer Clinical Practice Guideline rapid update v1.1 includes the latest guidance in a rapidly changing treatment landscape. This update addresses new immunotherapy approvals and practice-changing data, with updated expert recommendations and treatment algorithms related to biomarker testing and the treatment of esophageal, gastric, biliary tract, and colorectal cancers.
Read the SITC Gastrointestinal Cancer Clinical Practice Guideline as published in the Journal for ImmunoTherapy of Cancer (JITC) to view all of the latest recommendations!
|
|
Additional Programming and Events
|
|
|